Artwork

Content provided by Drug Discovery World and Drug Discovery World (DDW). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Discovery World and Drug Discovery World (DDW) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A new paradigm of appetite and hunger

20:43
 
Share
 

Manage episode 418202927 series 1919400
Content provided by Drug Discovery World and Drug Discovery World (DDW). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Discovery World and Drug Discovery World (DDW) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.

In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic.

The drug targets receptors in the gut where it triggers cholecystokinin (CCK), a GI system peptide hormone responsible for stimulating the digestion of fat and protein. CCK stimulates pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and sends a signal to the brain that one has had enough to eat.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

  continue reading

156 episodes

Artwork
iconShare
 
Manage episode 418202927 series 1919400
Content provided by Drug Discovery World and Drug Discovery World (DDW). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Drug Discovery World and Drug Discovery World (DDW) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.

In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic.

The drug targets receptors in the gut where it triggers cholecystokinin (CCK), a GI system peptide hormone responsible for stimulating the digestion of fat and protein. CCK stimulates pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and sends a signal to the brain that one has had enough to eat.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

  continue reading

156 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide